Detalhe da pesquisa
1.
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Lancet Oncol
; 16(4): e165-72, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25846096
2.
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
bioRxiv
; 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328215
3.
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.
Cancer Res
; 83(21): 3611-3623, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603596
4.
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Cell Rep
; 42(4): 112297, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36961816
5.
Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.
Lancet Oncol
; 16(7): e309-10, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26149875
6.
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
Cancer Cell
; 39(11): 1531-1547.e10, 2021 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34624218
7.
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Oncogene
; 38(37): 6399-6413, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31324888
8.
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
JCO Precis Oncol
; 20182018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30123863
9.
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Clin Cancer Res
; 24(1): 197-208, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051323
10.
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Elife
; 62017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28145866
11.
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Cell Rep
; 21(11): 3298-3309, 2017 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241554
12.
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Cancer Res
; 76(6): 1591-602, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825170
13.
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Nat Med
; 22(3): 262-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26828195
14.
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Clin Cancer Res
; 21(17): 3924-33, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25964297
15.
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Cancer Discov
; 5(7): 713-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25934077
16.
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Nat Commun
; 6: 6377, 2015 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25758528
17.
EMT twists the road to PI3K.
Cancer Discov
; 4(2): 149-51, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24501304
18.
Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Science
; 346(6216): 1480-6, 2014 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394791
19.
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Sci Signal
; 6(294): re6, 2013 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24065147
20.
Suppression of survival signalling pathways by the phosphatase PHLPP.
FEBS J
; 280(2): 572-83, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22340730